FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1972861806> ?p ?o ?g. }

• W1972861806 abstract "Successful therapeutic regimens in metastatic breast cancer (MBC) must balance efficacy and tolerability. Docetaxel/capecitabine is an active and commonly used doublet in this setting. Docetaxel upregulates thymidine phosphorylase and thus potentiates the antitumor effects of capecitabine. A schedule with split, low-dose docetaxel in combination with low-dose capecitabine could improve the therapeutic index of this regimen without compromising its clinical activity.Patients with previously untreated HER2/neu-negative MBC were eligible. Treatment consisted of docetaxel 25 mg/m2 on days 1 and 8 in combination with capecitabine 750 mg/m2 twice daily on days 1-14 of a 3-week cycle. Thirty-nine women were enrolled. Median age was 55 years (range, 36-75 years). Fourteen patients had triple-negative disease. Sites of metastasis were as follows: bone (n = 27); liver (n = 15); lung (n = 17); nonregional chest (n = 4); lymph nodes (n = 2); and skin (n = 1). Six patients had bone-only disease. All subjects had a performance status of 0/1. A total of 329 cycles were administered (median, 6; range, 1-50).Of 37 patients who received study treatment, 32 had evaluable disease, 1 had a complete response, and 15 had a partial response (overall response rate was 50% in evaluable patients and 43% in the intent-to-treat analysis). Six patients had stable disease. The overall clinical benefit rate was 69% for patients with evaluable disease and 60% overall. Fifteen patients had disease that progressed or had been withdrawn from study at the time of first evaluation. With a median follow-up of 25 months, median time to treatment failure was 4.25 months (95% CI, 1.5-7 months), and median overall survival has not yet been reached. Toxicity was moderate: 15 patients (41%) had grade 3/4 adverse events.Split, low-dose docetaxel and low-dose capecitabine is an active combination in the first-line treatment of patients with MBC. Toxicity with this schedule was manageable, making it an attractive regimen for further study in combination with targeted agents." @default.
• W1972861806 created "2016-06-24" @default.
• W1972861806 creator A5002438057 @default.
• W1972861806 creator A5019571467 @default.
• W1972861806 creator A5027287789 @default.
• W1972861806 creator A5028701291 @default.
• W1972861806 creator A5044737202 @default.
• W1972861806 creator A5057066889 @default.
• W1972861806 creator A5058967910 @default.
• W1972861806 creator A5060118680 @default.
• W1972861806 creator A5062422300 @default.
• W1972861806 creator A5063914778 @default.
• W1972861806 creator A5065074547 @default.
• W1972861806 creator A5066516369 @default.
• W1972861806 creator A5068401391 @default.
• W1972861806 date "2008-04-01" @default.
• W1972861806 modified "2023-09-24" @default.
• W1972861806 title "A Phase II Trial of Split, Low-Dose Docetaxel and Low-Dose Capecitabine: A Tolerable and Efficacious Regimen in the First-Line Treatment of Patients with HER2/neu–Negative Metastatic Breast Cancer" @default.
• W1972861806 cites W1971954228 @default.
• W1972861806 cites W2086399528 @default.
• W1972861806 cites W2099979628 @default.
• W1972861806 cites W2115228053 @default.
• W1972861806 cites W2131770017 @default.
• W1972861806 cites W2137909720 @default.
• W1972861806 cites W2138577761 @default.
• W1972861806 cites W2139248078 @default.
• W1972861806 cites W2169764884 @default.
• W1972861806 cites W2171172959 @default.
• W1972861806 cites W3012264001 @default.
• W1972861806 doi "https://doi.org/10.3816/cbc.2008.n.017" @default.
• W1972861806 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18621613" @default.
• W1972861806 hasPublicationYear "2008" @default.
• W1972861806 type Work @default.
• W1972861806 sameAs 1972861806 @default.
• W1972861806 citedByCount "10" @default.
• W1972861806 countsByYear W19728618062013 @default.
• W1972861806 countsByYear W19728618062019 @default.
• W1972861806 crossrefType "journal-article" @default.
• W1972861806 hasAuthorship W1972861806A5002438057 @default.
• W1972861806 hasAuthorship W1972861806A5019571467 @default.
• W1972861806 hasAuthorship W1972861806A5027287789 @default.
• W1972861806 hasAuthorship W1972861806A5028701291 @default.
• W1972861806 hasAuthorship W1972861806A5044737202 @default.
• W1972861806 hasAuthorship W1972861806A5057066889 @default.
• W1972861806 hasAuthorship W1972861806A5058967910 @default.
• W1972861806 hasAuthorship W1972861806A5060118680 @default.
• W1972861806 hasAuthorship W1972861806A5062422300 @default.
• W1972861806 hasAuthorship W1972861806A5063914778 @default.
• W1972861806 hasAuthorship W1972861806A5065074547 @default.
• W1972861806 hasAuthorship W1972861806A5066516369 @default.
• W1972861806 hasAuthorship W1972861806A5068401391 @default.
• W1972861806 hasConcept C121608353 @default.
• W1972861806 hasConcept C126322002 @default.
• W1972861806 hasConcept C141071460 @default.
• W1972861806 hasConcept C143998085 @default.
• W1972861806 hasConcept C197934379 @default.
• W1972861806 hasConcept C2775930923 @default.
• W1972861806 hasConcept C2776694085 @default.
• W1972861806 hasConcept C2777909004 @default.
• W1972861806 hasConcept C2778375690 @default.
• W1972861806 hasConcept C2778822529 @default.
• W1972861806 hasConcept C2781190966 @default.
• W1972861806 hasConcept C2781413609 @default.
• W1972861806 hasConcept C526805850 @default.
• W1972861806 hasConcept C530470458 @default.
• W1972861806 hasConcept C71924100 @default.
• W1972861806 hasConcept C90924648 @default.
• W1972861806 hasConceptScore W1972861806C121608353 @default.
• W1972861806 hasConceptScore W1972861806C126322002 @default.
• W1972861806 hasConceptScore W1972861806C141071460 @default.
• W1972861806 hasConceptScore W1972861806C143998085 @default.
• W1972861806 hasConceptScore W1972861806C197934379 @default.
• W1972861806 hasConceptScore W1972861806C2775930923 @default.
• W1972861806 hasConceptScore W1972861806C2776694085 @default.
• W1972861806 hasConceptScore W1972861806C2777909004 @default.
• W1972861806 hasConceptScore W1972861806C2778375690 @default.
• W1972861806 hasConceptScore W1972861806C2778822529 @default.
• W1972861806 hasConceptScore W1972861806C2781190966 @default.
• W1972861806 hasConceptScore W1972861806C2781413609 @default.
• W1972861806 hasConceptScore W1972861806C526805850 @default.
• W1972861806 hasConceptScore W1972861806C530470458 @default.
• W1972861806 hasConceptScore W1972861806C71924100 @default.
• W1972861806 hasConceptScore W1972861806C90924648 @default.
• W1972861806 hasLocation W19728618061 @default.
• W1972861806 hasLocation W19728618062 @default.
• W1972861806 hasOpenAccess W1972861806 @default.
• W1972861806 hasPrimaryLocation W19728618061 @default.
• W1972861806 isParatext "false" @default.
• W1972861806 isRetracted "false" @default.
• W1972861806 magId "1972861806" @default.
• W1972861806 workType "article" @default.